Parallel Health

Based in the US, Parallel Health specializes in Microbiome Dermatology™, providing innovative skincare solutions through personalized health management and advanced microbiome analysis. Founded in 2020 and headquartered in San Francisco, US, Parallel Health focuses on transforming skincare through microbiome research. The firm raised USD 3. 8 mn in a Seed funding round in October 2021, led by Rhythm Venture Capital.

This was the company's first funding round, marking its entry into the investment landscape. Parallel Health offers a unique suite of products and services centered around Microbiome Dermatology™, primarily through its MD-03 Protocol™. This three-step system includes an at-home Skin Discovery Test that utilizes whole genome sequencing to analyze the skin's microbial composition, followed by personalized 1:1 clinical consultations for tailored treatment recommendations, and culminating in the delivery of a Custom Active Phage Serum. The phage serum combines microbiome-nourishing ingredients and a targeted phage cocktail designed to selectively eliminate pathogenic bacteria while preserving beneficial microbes.

The company aims to address complex skin conditions such as acne, rosacea, eczema, melasma, and signs of aging. Parallel Health primarily serves consumers in North America and select international markets, targeting individuals seeking personalized and scientifically-backed skincare solutions, including those with chronic skin issues. Parallel Health generates revenue through a subscription-based model where customers engage in ongoing services for skin health management. The primary offerings include the Skin Discovery Test priced at USD 495, which is conducted every six months, combined with a monthly consultation and support fee provided at no initial cost after the first month, and a monthly charge of USD 195 for the Custom Active Phage Serum.

This structured approach fosters long-term relationships with clients, enhancing their experience while addressing their skin health needs effectively. By providing these tailored services directly to consumers, Parallel Health establishes a direct-to-consumer revenue stream that aligns with modern healthcare trends emphasizing personalized treatment. Looking ahead, Parallel Health plans to expand its product offerings and geographic reach. Upcoming launches include enhancements to the MD-03 Protocol™ designed for additional skin conditions, with anticipated release dates in 2023.

The firm is also targeting expansion into new international markets across Europe and Asia by late 2024. The recent funding of USD 3. 8 mn will be crucial for supporting product development and market penetration initiatives.